The Mayo Clinic Study of Aging (MCSA) was established in 2004 as a population-based study of aging, mild cognitive impairment (MCI) and dementia in Olmsted County, MN.
The specific aims were designed to estimate the population prevalence of normal cognition, MCI and its subtypes, to estimate incidence rates of MCI and dementia, and begin to explore predictors for these conditions. In the proposed renewal period, we plan to refine the incidence rates for MCI and dementia and to evaluate the utility of a variety of traditional and novel factors including medical comorbidities, biomarkers and imaging measures for predicting MCI and dementia. We propose the following specific aims:
Specific Aim 1 : To obtain stable estimates of incidence rates for normal cognition to MCI, its subtypes, and dementia, and its subtypes including Alzheimer's disease, and from MCI to dementia by sex and presumed etiology.
Specific Aim 2 : To investigate potential risk factors or predictors including clinical, biochemical and imaging markers for transitions from normal cognition to MCI and to dementia by sex and etiology, and from MCI to dementia by sex and etiology.
Specific Aim 3 : To explore multivariable models of risk factors or predictors resulting from Specific Aim 2 for transitions from normal cognition to MCI and dementia by sex and etiology and for MCI to dementia by subtypes and sex.
Specific Aim 4 : To provide subjects and biological materials for related research projects and provide a platform for training new investigators. To accomplish these goals, the current cohort will be replenished to 2000 persons (approximately 1650 cognitively normal and 350 MCI) by the time of the proposed grant initiation. We will use the Mayo Clinic medical records-linkage system to validate medical comorbidities and evaluate their role as predictors for our study outcomes. At the initiation of the proposed grant renewal period, we will have completed over 1500 quantitative MRI scans on the participants and will be in the process of obtaining cerebrospinal fluid and Pittsburgh Compound B scans on 600 persons randomly selected from the cohort. These measures will be combined with annual plasma A (3 measures and genotype information to develop multivariable prediction models. This proposed study will represent one of the first attempts to combine clinical, neuroimaging and biomarker information as predictors of cognitive impairment in a large non-demented population-based cohort over a period of 5 - 10 years.

Public Health Relevance

We urgently need techniques to predict which individuals will develop mild cognitive impairment and Alzheimer's disease (AD) in the future. The Mayo Clinic Study of Aging is designed to explore the utility of common and novel medical risk factors, neuroimaging measures and biomarkers to predict AD in a population-based setting. This information is essential for public health purposes and for the planning of clinical trials for the prevention of AD.

National Institute of Health (NIH)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Anderson, Dallas
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Jaeger, Philipp A; Lucin, Kurt M; Britschgi, Markus et al. (2016) Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. Mol Neurodegener 11:31
Teeters, D Alex; Moua, Teng; Li, Guangxi et al. (2016) Mild Cognitive Impairment and Risk of Critical Illness. Crit Care Med 44:2045-2051
Jack Jr, Clifford R; Knopman, David S; Chételat, Gaël et al. (2016) Suspected non-Alzheimer disease pathophysiology--concept and controversy. Nat Rev Neurol 12:117-24
Sprung, Juraj; Roberts, Rosebud O; Knopman, David S et al. (2016) Association of Mild Cognitive Impairment With Exposure to General Anesthesia for Surgical and Nonsurgical Procedures: A Population-Based Study. Mayo Clin Proc 91:208-17
Raman, Mekala R; Schwarz, Christopher G; Murray, Melissa E et al. (2016) An MRI-Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. J Neuroimaging 26:264-8
Wennberg, Alexandra M V; Gustafson, Deborah; Hagen, Clinton E et al. (2016) Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging. J Alzheimers Dis 53:573-81
Graff-Radford, Jonathan; Lesnick, Timothy G; Boeve, Bradley F et al. (2016) Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. Mov Disord 31:989-94
Lowe, Val J; Curran, Geoffry; Fang, Ping et al. (2016) An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun 4:58
Sassi, Celeste; Ridge, Perry G; Nalls, Michael A et al. (2016) Influence of Coding Variability in APP-Aβ Metabolism Genes in Sporadic Alzheimer's Disease. PLoS One 11:e0150079
Tosto, Giuseppe; Bird, Thomas D; Bennett, David A et al. (2016) The Role of Cardiovascular Risk Factors and Stroke in Familial Alzheimer Disease. JAMA Neurol 73:1231-1237

Showing the most recent 10 out of 494 publications